Unlock instant, AI-driven research and patent intelligence for your innovation.

Methods and compositions for treating diabetes

A composition, a technology for type 2 diabetes, applied in drug combinations, metabolic diseases, pharmaceutical formulations, etc.

Inactive Publication Date: 2018-11-30
ORAMED
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] So far, GLP-1 analogues are only available as injectable formulations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for treating diabetes
  • Methods and compositions for treating diabetes
  • Methods and compositions for treating diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0140] Example 1: Identification of Effective Emulsifiers for Homogeneous Therapeutic Protein / Fish Oil Formulations

[0141] Previous formulations of insulin in fish oil were found to precipitate over time; therefore, they were inconvenient for large-scale preparation of pharmaceutical dosage forms. The new formulation contained 3.375 g of SBTI per 22.5 g of fish oil and contained the following emulsifiers to be tested: lecithin (test sequence 1), polysorbate 80 (Tween-80) (sequence 2) or (Sequence 3), alone or in combination with each other or with glyceryl monostearate (GMS) ( figure 1 ). Subsequently, the most promising formulations (indicated by asterisks) were melted by (which is a waxy solid at room temperature), which is then regenerated by adding it to fish oil. After cooling the mixture, the solid components are added in powder form in the following order: EDTA, SBTI, aprotinin and insulin; and the resulting liquid is mixed and homogenized in a roller mill.

Embodiment 2

[0142] Example 2: In vivo testing of various emulsifier formulations

[0143] Materials and Experimental Methods

[0144] preparation

[0145] The formulations tested in Experiments 2A and 2B are shown in Table 1. The percentage of emulsifier is expressed as a weight / weight ratio relative to the weight of liquid present.

[0146] Table 1

[0147]

[0148]

[0149] feed

[0150] Animal Health: Only clinically veterinary-certified healthy pigs were used for research. Residence: When with CVC, live alone, other times, live in groups. Cushion: concrete + wood chips. Lighting: 12-12h photoperiod. Temperature: 19-25°C

[0151] identification

[0152] Uniquely identify each animal by ear tag.

[0153] experimental design

[0154] Animals were fasted for 24-36 hours prior to testing. Drink water freely.

[0155] Animals were anesthetized with 20 mg / kg Ketamine + 2 mg / kg Xylazine. Fasted and anesthetized pigs were placed in left lateral recumbency, after which the liq...

Embodiment 3

[0163] Example 3: Oral insulin / oral exenatide combination significantly reduces blood sugar levels and prevents postprandial blood sugar fluctuations

[0164] Materials and Experimental Methods

[0165] animal

[0166] Healthy 25-30 kg, 3-4 month old pigs were used.

[0167] experimental design

[0168] Pigs were fasted for 24-36 hours before the start of the study. Replace the CVC every five days (unless circumstances warrant an earlier replacement). After being connected to endotracheal tube and respirator (2 L O per minute) 2 , when needed, 3-5% isoflurane), the animal was anesthetized by face mask administration of isoflurane, then placed in left lateral recumbency, and under endoscopic guidance, the capsule was administered directly into ten duodenum. When both oral insulin and oral exenatide are administered, the oral exenatide is delivered first, followed by the oral insulin within 2-10 minutes. The pigs were returned to the pen to fully recover from the anesthes...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.

Description

[0001] This application is a divisional application of the Chinese patent application with the application number 201380012325.5, the application date is January 3, 2013, and the invention title is "method and composition for treating diabetes". [0002] This application claims the benefit of US Provisional Application 61 / 631,339, filed January 3, 2012, which is hereby incorporated by reference in its entirety. technical field [0003] Methods and compositions for treating diabetes are disclosed herein. Background technique [0004] Diabetes, especially type 2 diabetes mellitus (NIDDM), has become a global epidemic in the 21st century. Uncontrolled diabetes can cause numerous long-term complications, including those affecting the kidneys, legs, feet, eyes, heart, nerves, and blood circulation. Prevention of these conditions requires comprehensive treatment and requires lifestyle adjustments and medications. Many effective antidiabetic drugs are available and are generally ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K38/28A61K38/26A61K38/55A61K31/198A61K9/48A61P3/10
CPCA61K38/26A61K38/55A61K45/06A61K31/198A61K9/4891A61K9/5005A61K38/28A61P3/10A61K2300/00A61K9/4808A61K9/4875A61K38/56A61K38/57
Inventor M·基德隆
Owner ORAMED